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Angiogenesis is a vital process resulting in the formation of new blood vessels. It is normally a highly regulated process that occurs
during human development, reproduction, and wound repair. However, angiogenesis can also become a fundamental pathogenic
process found in cancer and several other diseases. To date, the inhibition of angiogenesis has been researched at both the bench
and the bedside. While several studies have found moderate improvements when treating with angiogenesis inhibitors, greater
success is being seen when the inhibition of angiogenesis is combined with other traditional forms of available therapy. This
review summarizes several important angiogenic factors, examines new research and ongoing clinical trials for such factors, and
attempts to explain how this new knowledge may be applied in the ﬁght against cancer and other angiogenic-related diseases.
1.Introduction
For over 35 years, scientists have been trying to fully
understand the process of both normal and pathogenic
angiogeneses, hoping to apply their ﬁndings to the world of
clinical medicine and therapeutics. Angiogeneses is a critical
process involving the formation of new blood vessels from
preexisting vessels [1]. Normal angiogeneses is an essential
process the body employs during fetal development, wound
healing, ovulation, as well as growth and development [2].
Angiogeneses provides developing and healing tissues with
vitalnutrientsandoxygen[3].Whenangiogenesesgoesawry,
pathological problems often ensue. The understanding of
normal and pathogenic angiogeneses has been a major focus
of both cancer biology and clinical medicine for the past few
decades.
In the past, research in angiogeneses was closely inter-
twined with cancer biology. The importance of angiogeneses
in tumor growth was initially hypothesized in 1971, when
Judah Folkman theorized that solid tumors possess limited
resources that the many actively proliferating cancer cells
ﬁght for. Increased interstitial pressure within the tumor also
inhibitsthediﬀusionofmetabolitesandnutrientsessentialto
the growth and survival of tumor cells [4]. This environment
causes tumor cells to induce the sprouting of new blood
vessels from the established vasculature, creating a vascular
system within the tumor, thus enabling tumor cells to obtain
the oxygen and nutrients they need to survive and multiply.
Understanding these principles led to the idea that the
inhibitionoftumorangiogenesescouldbeavaluabletherapy
against cancer [1]. This sparked research into the proteins
that regulate this process, both angiogeneses inhibitors and
promoters. Since that time, many proteins and regulators
of angiogeneses have been discovered and their role in the
process deﬁned.
Although cancer has traditionally been the most exten-
sively studied angiogenic-dependent disease, several other
conditionshavealsoshownarelianceonangiogeneses.Some
of these include psoriasis, endometriosis, arthritis, macular
degeneration, regional ileitis, and atherosclerosis [5]. The
emergence of other diseases connected to angiogeneses
has led to increased research on angiogeneses as a whole.
Recently, new drugs have been developed that are capable
of targeting many of the regulators of angiogeneses [6].
Currently, several drugs have been approved by the FDA for
the treatment of angiogeneses-dependent diseases including
Avastin for colorectal cancer, Tarceva for lung cancer, and




































Figure 1: Blood Vessels. The cardiovascular system main components include arteries, arterioles, capillaries, venules, and veins. Each vessel
has cellular diﬀerences from the other types of vessels and this is highlighted above.
are in late-stage clinical testing. This review will focus on
the current knowledge of angiogeneses in health and dis-
ease, some important angiogenic promoters and inhibitors,
and ongoing research and developments as they relate to
oncology. Increasing the mechanistic understanding of these
processes will improve the development of more eﬃcient
angiostatic treatments in cancers.
2. Normal Blood Vessel Formation
The cardiovascular system distributes blood, and thus oxy-
gen and nutrients, throughout the body. The system consists
of arteries, arterioles, capillaries, venules, and veins. The
microvasculature is considered the portion of the circulatory
system composed of the smallest vessels, such as the capil-
laries, arterioles, and venules. The microvasculature is a very
dynamic and complex system, capable of constant change,
while the larger blood vessels are more permanent structures
with very little plasticity. As illustrated in Figure 1, capillaries
are hollow tubes composed of endothelial cells (ECs) which
are supported by pericytes. Unlike capillaries, arteries and
veins have several distinct layers including the tunica intima,
the tunica media, and tunica adventitia in the largest vessels
(composition of each detailed in Figure 1). Due to the
thickness of these structures, arteries, arterioles, venules, and
veins are all considered conduit vessels. Capillaries are the
most important vessels in cardiovascular system. The thin
walls of these microscopic vessels allow for the exchange of
oxygen and nutrients between the blood and tissues [7]. The
formationoftheinitialvascularplexuswithineachtissueand
theformationofthemajorbloodvesselsconductingbloodto
and from the heart are hard wired into the developmental
system [8]; these networks are formed independent of
oxygen concentration. In contrast, the pattern of capillary
(microvasculature) development within each tissue is driven
by local oxygen demand, and is therefore unique to each
tissue [8].
Blood vessels comprising the microvasculature are
formed in adults via two diﬀerent mechanisms: vasculo-
genesis and angiogeneses. Both processes normally occur
during embryonic development; however, special circum-
stances allow these processes to be initiated during adult
life. Vasculogenesis is the de novo formation of ECs from
angioblasts. This process helps form a primitive vascular
labyrinth of small capillaries [9]. Angiogeneses is the process
in which ECs sprout from preexisting blood vessels. The
ECs then migrate and proliferate to form a cord-like
structure.
2.1. Vasculogenesis: Current Concepts and Challenges. The
establishment of fetal vasculature begins with heman-
gioblasts, primitive cells of mesodermal origin [10]. Heman-
gioblasts help form “blood islands”, clusters of cells that
have a designated spatial arrangement that facilitates their
function. Hematopoietic stem cells (HSCs), which later
become hematopoietic cells, are found at the center of these
islands. Angioblasts, cells that diﬀerentiate into ECs, are
found at the periphery of the blood islands [11]. The adult
stem cells found within bone marrow (instead of blood






















Figure 2: Adult Vasculogenesis. The ﬁgure illustrates the process where MAPCs become angioblasts, then circulating EPCs and ECs as part
of the primitive vascular labyrinth.
than originally thought, and are now considered multipotent
a d u l tp r o g e n i t o rc e l l s( M A P C s )[ 12]. MAPCs are capable of
diﬀerentiating into ECs when removed from bone marrow
andculturedonﬁbronectinwithvascularendothelialgrowth
factor-A (VEGF-A) [13]. In addition, MAPCs are capable
of diﬀerentiating into skeletal muscle, cardiac muscle, and
vascular endothelium after bone marrow transplantation
[12].
As demonstrated in Figure 2, it is currently believed that
vasculogenesis originates when MAPCs in bone marrow
diﬀerentiate into early endothelial progenitor cells (EPCs)
[13, 14]. As MAPCs evolve into EPCs, they gain hematopoi-
etic and endothelial lineage-speciﬁc markers such as VEGF
receptor-2 (VEGFR-2) and CD34 [15, 16]. EPCs in the bone
marrow remain undiﬀerentiated in one of two zones. The
ﬁrst zone is known as the vascular zone, and it consists
of EPCs in either the S phase or G2M phase of the cell
cycle. These cells are capable of diﬀerentiating and entering
peripheral circulation upon receiving the correct signals
[14, 17]. The second zone is known as the osteoblastic zone,
where EPCs are maintained in the G0 phase of the cell
cycle. These cells are not actively dividing, and therefore
not readily available for release into circulation [14, 18].
The balance between these two functional compartments
is maintained by cytokines present in the bone marrow’s
extracellular matrix (ECM) and on bone marrow stromal
cells [19] .T h eb o n em a r r o ws t r o m a lc e l l sa n dE C Mp r e s e r v e
levels of cytokines bound to either ECM proteins or cell
membranes. The cytokines can be cleaved by proteinases and
activated. To illustrate, matrix metalloproteinases (MMPs)
help mediate the digestion of ECM which leads to the release
of membrane-bound cytokines. This allows the release of
VEGF-A, an important regulator of both angiogeneses and
vasculogenesis [20]. Evidence has suggested that MMP-9 is
capable of mobilizing EPCs to enter the vascular zone and
eventuallybereleasedintotheperipheralcirculation[14,17].
Malignant transformation, tissue injury, or ischemia can
induce systemic release of VEGF-A, activating bone marrow
progenitor stem cells [15].
A recent study veriﬁed altered levels of MMP-9 and
VEGF-A in patients with early-stage breast and colorectal
cancer when compared to normal patients [57]. Healthy vol-
unteersshowedVEGF-Aplasmalevelsaveraging37.6μg/mL,
while the breast cancer patients had average plasma concen-
trations of 52.9μg/mL and colorectal cancer patients plasma
concentrations averaged 109.6μg/mL. MMP-9 plasma con-
centrations for healthy volunteers averaged 169ng/mL, while
breast cancer patients had plasma concentrations averag-
ing 237.8ng/mL and colorectal cancer patients averaged
370.1ng/mL. The patients underwent surgical resection of
their primary tumors and the levels of MMP-9 and VEGF-
Aw e r em e a s u r e db e t w e e n7a n d8w e e k sp o s t s u r g e r y .
These same patients saw a decrease in their MMP-9 and
VEGF-A plasma levels [57]. The breast cancer patients saw
a decrease in the average VEGF-A plasma concentration
from 52.9μg/mL to 43.8μg/mL and their MMP-9 levels
dropped from an average of 237.8ng/mL to 109.6ng/mL.
The colorectal cancer patients saw similar changes after
their tumors were removed with their average VEGF-A
plasma levels dropping from 109.6μg/mL to 57.6μg/mL
and their MMP-9 plasma levels going from 370.1ng/mL
to 190.3ng/mL [57]. This evidence shows the direct eﬀect
that malignancy can have on factors important to both
vasculogenesis and angiogeneses.4 Journal of Oncology
Table 1: Factors regulating angiogenesis.
Angiogenesis factors Biological activities
Vascular endothelial growth
factor (VEGF)
(i) Promoter of angiogeneses and vasculogenesis [21]
(ii) Stimulates microvascular EC proliferation [22, 23]
(iii) Enhances EC migration and sprouting [24, 25]
(iv) Inhibits EC apoptosis [26]
(v) Increases EC permeability [27–29]
Fibroblast growth factor (FGF)
(i) Stimulates EC proliferation [30]
(ii) Promotes microvessel tube formation [30]
(iii) Promotes EC migration [30]
(iv) Important promoter of blood vessel remodeling after tissue injury [31]
Angiopoieten-1 (Ang-1)
(i) Recruits pericytes to recently created blood vessels [32]
(ii) Helps promote EC survival and sprout formation [32, 33]
(iii) Increases the diameter of blood vessels endothelium [34]
Angiopoieten-2 (Ang-2) (i) Antagonist of Tie-2 receptor, reduces levels of pericytes [35]
(ii) Increases plasticity of newly formed blood vessels [36]
Platelet-derived growth
factor (PDGF)
(i) Increases capillary wall stability [3]
(ii) Stimulates the proliferation of cultured pericytes and SMCs [37]
(iii) Increases DNA synthesis on capillary ECs [38]
(iv) Stimulate formation of angiogenic sprouts in vitro [38]
Transforming growth
factor-β (TGF-β)
(i) At low doses upregulates angiogenic factors and proteinases [39]
(ii) At high doses, inhibits EC growth, promotes reformation of BM and stimulates SMC reformation
[39]
(iii) Stimulates or inhibits EC tube growth [39]
(iv) Signals inﬂammatory mediators such as ﬁbroblasts and monocytes [3, 40, 41]
(v) Enhances integrity of vessel walls [42]
Integrin αVβ3
(i) Binds and activates MMP2 to help break down ECM [43]
(ii) Helps regulate cell attachment, spreading, and migration [44]
(iii) Shows Increased activity near wound sites [45]
(iv) Localized to ECs at ends of growing vessels during EC sprouting [46]
Integrin αVβ5 ( i )I n t e r a c t sw i t hV E G Ft op r o m o t ea n g i o g e n e s e s[ 47]
VE cadherin
(i) Thought to mediate passage of molecules across endothelium [28, 29]
(ii) Regulates CD growth through contact inhibition [48]
(iii) Helps prevent EC apoptosis by promoting VEGFs signal [49]
(iv) Helps stabilize the branches and sprouts produced during angiogeneses [48]
Tumor necrosis
factor-α (TNF-α)
(i) Stimulates angiogeneses in vivo [50]
(ii) Stimulates EC tube formation in vitro [51]
Transforming growth
factor-α (TGF-α)
( i )P r o m o t e sE Cp r o l i f e r a t i o n[ 50]
(ii) Stimulates angiogeneses in vivo [50, 52]
Angiogenin (i) Promotes angiogeneses in vivo [53]
(ii) Assists EC adhesion and spreading in vitro [54]
Angiotropin
(i) Helps activate microvascular ECs during wound healing [38]
(ii) Stimulates angiogeneses in vivo [38]
(iii) Randomly induces capillary EC migration [55]
Matrix metalloproteinase-9
(MMP-9) (i) Thought to help mobilize EPCs by cleaving ECM [17]
Stromal-cell-derived
factor-1 (SDF-1) (i) Helps guide EPCs to ischemic areas during angiogeneses [56]
During the process of vasculogenesis, EPCs that enter
the peripheral circulation migrate to the areas where the
vasculature will be established. The chemokine stromal-cell-
derived factor-1α (SDF-1α) helps mediate the migration of
many stem cells, including EPCs. SDF-1α is upregulated
during hypoxic conditions due to increased levels of VEGF-1
[56]. Once released, SDF-1α acts as a key homing signal,
helping to guide EPCs to areas of ischemia [58, 59]. The
guided cells are still considered early EPCs because they are
positive for CD133, CD34, and VEGFR-2 (as demonstrated
in Figure 2)[ 19]. While in circulation, the EPCs continue
to diﬀerentiate. They begin this process by losing the
CD133 marker, and gaining EC-speciﬁc markers such as
von Willebrand Factor (vWF), CD31, and VE cadherin
[60]. EPCs normally compose approximately 0.002% of
the mononuclear cell fraction of blood [61]. However,Journal of Oncology 5
if neovascularization is required, vasculogenic stimuli are
released, increasing the circulating concentration of EPCs
[62–64]. Clinical trials have demonstrated this phenomenon
using patients who either suﬀered burns or underwent
coronary artery bypass graft surgery [65]. Both patient
groups saw a 50-fold increase in EPC levels within the ﬁrst
6 hours after the initiating event, with a return to basal levels
within 72 hours. It is believed that this transient increase in
EPC levels caused by the vascular and tissue trauma induces
the release of several cytokines, including VEGF, promoting
EPC mobilization and the initiation of vasculogenesis [65].
After EPCs arrive and enter the target tissue, some
continue their diﬀerentiation into mature ECs [19]. It is
thought that the cells that do not diﬀerentiate into mature
ECs act as a source of proangiogenic cytokines [19]. The
maturation into ECs is marked by the loss of the CD34
marker on the cell surface.
Vasculogenesis that occurs during postfetal life in re-
sponse to angiogenic cytokines has a few key diﬀerences
from the vasculogenesis that occurs during embryonic life.
One major diﬀerence is that the formation of the initial
vascular plexus in embryonic life is not driven by insuﬃcient
oxygen like the vasculogenesis that occurs later in life [8]. An
imbalance in oxygen supply and demand can cause hypoxia
resulting in an induction of cytokine production or release
from cells throughout the body. One such cytokine released
duringhypoxicconditionsisVEGF.AfterVEGFisreleased,it
binds to VEGF receptors on ECs. This leads to the activation
of signal transduction pathways capable of stimulating both
angiogeneses and vasculogenesis. The hypoxic conditions
seen in tumor cells have been studied and factors associated
with vasculogenesis and angiogeneses have been monitored
to detail their relationships. Many of these factors have been
listed in Table 1.
As discussed above, Zaman’s work on colorectal and
breast cancer patients speciﬁcally showed increased con-
centrations in VEGF-A and MMP-9 plasma levels due to
malignancy. These levels are reduced after the tumor is
removed, and thus levels of angiogeneses and vasculogenesis
are decreased. Another diﬀerence in the two types of
vasculogenesis is that most of the cells recruited to sites of
vasculogenesis during postembryonic life are inﬂammatory
cells and are not incorporated into the new capillaries or
remodeling arteries. The postembryonic form of vasculo-
genesis is much more similar to angiogeneses then the
embryonic form of vasculogenesis and this is illustrated
by the similar factors that are vital to postembryonic
vasculogenesis and angiogeneses.
2.2. Angiogeneses: Current Concepts, Known Factors, and
Challenges. In contrast to vasculogenesis, angiogeneses is
the expansion of preexisting vasculature, such as a vascular
labyrinth of capillaries, by means of budding and branching
into a functional capillary bed which is illustrated in
Figure 3. This normally occurs in very organized manner
forming what is known as primary vascular trees [66].
Like vasculogenesis, angiogeneses occurs most often during
embryonic development; however, it can also occur in adult
life in response to speciﬁc stimulations. Nonpathogenic
angiogeneses can be seen in adults during the ovarian cycle,
in skeletal and cardiac muscle during times of exercise and
training, as well as during the process of wound healing [3].
The process of angiogeneses is very closely regulated.
Stimulation of angiogeneses occurs by growth factors such
as VEGF and FGF (see Figure 3, Table 1). New blood vessel
formation actually begins with the removal of mural cells
(pericytes) from preexisting blood vessels. The absence of
these pericytes initiates the degradation of the EC basement
membrane and extracellular matrix, a process which is aided
by MMPs [67].
As the basement membrane and extracellular matrix are
being degraded, ECs begin proliferating and migrating with
the help of soluble growth factors. The ECs will continue
to grow until they form an unstable microvessel. Following
the formation of this small blood vessel, mesenchymal cells
are recruited to the vessel, where they are subsequently
diﬀerentiated into pericytes. After diﬀerentiation, cell-cell
contact between pericytes and ECs occurs. Stable blood
vessels are then formed and blood ﬂow can be established.
This process of angiogeneses is visualized in Figure 3. Vessels
made from ECs not covered with pericytes are unstable, and
undergo regression [3, 21]. There are many known factors
that help regulate angiogeneses. Some of the known factors
are touched upon in Table 1 and discussed in further detail
below.
2.3. Angiogenic Promoters: Current Research and
Clinical Implications
2.3.1.VascularEndothelialGrowthFactor. VEGFisanimpor-
tant regulator of both vasculogenesis and angiogeneses
[21]. Several cell types including ﬁbroblasts, ECs, and ker-
atinocytes release a small amount of VEGF throughout life.
ThelossofaVEGFallelealwaysresultsinembryoniclethality
[35]. Increased levels of VEGF are seen when angiogeneses is
necessary, such as during active wound healing [68].
There are currently six known monomers of VEGF that
arise from alternative splicing of a single gene with eight
exons. The documented isoforms contain 121, 145, 165, 183,
189 or 206 amino acids [69–72]. Some of these isoforms
remain associated with cells or membranes, while others are
released extracellularly. Despite these diﬀerences, all of them
have identical biological activities [73].
VEGF interacts with two diﬀerent receptor tyrosine
kinases, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1), to alter
angiogeneses. VEGFR-1 interacts very strongly with VEGF,
but this interaction plays a minor role in the events of
angiogeneses [74]. The interaction of VEGFR-2 with VEGF
is a major contributor to the mitogenic, chemotactic, angio-
genic, and increased permeability eﬀects of VEGF. VEGFR-
2 expression has been observed on both endothelial and
hematopoietic precursors [22].
Experiments have shown that VEGF has the ability to
stimulate microvascular EC proliferation [22, 23]. VEGF is
also capable of enhancing EC migration [24], inhibiting EC





























Figure 3: Tumor Inﬂuenced Angiogeneses. The stepwise process of angiogeneses begins with ECM and BM breakdown, followed by EC
proliferation, EC migration and ﬁnally re-formation of stable blood vessel. Tumor cells will secrete a variety of factors to ensure that the new
blood vessels formed are fed directly to the tumor tissue.
from preexisting vasculature [25]. VEGF helps induce EC
migration and sprouting by upregulating integrin receptors
αVβ3, α1β1, and α1β2 (discussed below) [27, 75]. VEGF also
helps activate MMPs, an important step in the initial stages
of angiogeneses.
VEGF is upregulated during hypoxic conditions via
the following mechanism, which involves hypoxia-inducible
factor-1 (HIF-1), a protein released during oxygen stress
[76]. Responses to ischemia are mostly regulated by cells
within the ischemic area monitoring oxygen concentrations.
After sensing reduced concentrations, these cells increase
their expression of genes encoding vascular growth factors.
At the heart of this pathway is HIF-1, a heterodimeric
transcriptionfactorcomposedoftheconstitutivelyexpressed
HIF-1β, and the oxygen-sensitive HIF-1α subunits [77, 78].
Although HIF-1α is also constitutively expressed, it is broken
down within adequately oxygenated and perfused tissue.
When tissues are deprived of oxygen, the breakdown of HIF-
1α is inhibited. HIF-1α begins to build up and eventually
dimerizes with HIF-1β. This complex then binds to DNA,
helps recruit coactivators, and activates transcription of its
target genes [79]. This system induces expression of several
vasculogenic and angiogenic growth factors including VEGF
and PLG in response to hypoxia [80]. HIF-1 is also required
for expression of VEGFR-1 on EPCs in the bone marrow and
the chemotactic migration of EPCs towards a VEGF gradient
[79].
The use of anti-VEGF drugs has been applied to many
diﬀerent ﬁelds of medicine. The American Academy of
Ophthalmology recently published a report stating that the
use of anti-VEGF pharmacotherapy is a safe and eﬀective
treatment for neovascular age-related macular degeneration
(AMD) [81]. Anti-VEGF signaling pathway drugs have also
been tested in a large number of clinical and laboratory
studies aimed at preventing angiogeneses associated with
cancer. Some of these drugs target VEGF (Avastin), while
others target the VEGFRs (Nexavar and Sutent) [82].
Although these drugs have seen dramatic results in animal
models [83–85], the results in many of the clinical trials have
been mixed [86]. There have been clinical trials which show
as many as 94% of invasive carcinomas and 88% of in situ
carcinomas having a complete response [87]. These same
patients saw no recurrence during the ﬁve-year followup
[87]. However, many other angiogeneses inhibitors targeting
VEGF signaling pathways have failed to produce the same
long-term responses in a majority of their patients [86, 88,
89].Ashort-termresponseofeithertumorstasisorincreased
survival was normally observed in these patients [90];
however after the initial beneﬁt, most patients experienced
tumorgrowthafterseveralmonths[90].Thesecontradictory
results have changed the philosophy on the resistance of
tumors to antiangiogenic treatments, as well as the vascular
makeup thought to be associated with the blood vessels that
support tumors. These concepts will be further explored in
the future directions section.
Inducing neovascularization in ischemic diseases such
as chronic wounds and myocardial infarction is also a
very active area of research and is leading to a greaterJournal of Oncology 7
understanding of how VEGF works in the body. Several
groups have attempted to induce angiogeneses in ischemic
tissue through local delivery of the VEGF gene or protein.
In clinical trials, local delivery of pro-VEGF growth factors
has induced modest levels of neovascularization in ischemic
tissue [91]. However, the amount of angiogeneses was
inadequate as a monotherapeutic treatment [91]. This infor-
mation is also valuable for the ﬁeld of tumor angiogeneses.
It is evident that although VEGF is an important part of
angiogeneses, controlling its level alone is not enough to
regulate angiogeneses in normal tissues or tumors.
2.3.2. Fibroblast Growth Factor. Another important set of
proteins mediating angiogeneses is the FGF family. FGFs
are soluble growth factors that come in an acidic (aFGF)
and basic (bFGF) variety. Both types consist of widespread
polypeptides that are powerful inducers of EC migration,
proliferation, and microvessel tube formation (Figure 3)[ 3,
30]. While VEGF is a speciﬁc mitogen for ECs, the same
cannot be said for FGF. FGF is pleiotropic; it stimulates
proliferation in nearly all cells derived from embryonic
mesoderm or neuroectoderm [92]. Recent evidence suggests
that FGF does not play a major role in generalized angio-
geneses in vivo, as mice deﬁcient in both forms of FGF
underwent normal development [31]. Instead, FGF seems
to be more important in the remodeling of damaged blood
vessels [31] which can occur during both wound healing and
tumorangiogeneses.FGFisgenerallyfoundinthecytoplasm
of cells or bound to heparin in the ECM [93, 94]. After
tissue damage occurs, it appears that FGF is released from
the damaged cell(s). This local release of FGF is thought
to help promote angiogeneses at the site of the damaged
vessel.
One group recently studied the role of FGF in vascular
integrity and human saphenous vein ECs in vitro by
disrupting FGF signaling in bovine aortic endothelial cells
[95]. They also disrupted the FGF signaling pathway in adult
mouse and rat ECs in vivo using soluble FGF traps or a
dominant inhibitor of all FGF receptors [95]. Inhibition
of this signaling pathway led to a loss of function in the
adherens and tight junctions, which caused the loss of EC’s,
severe impairment of the endothelial barrier function, and
ﬁnally, disintegration of the vasculature [95]. This experi-
ment showed another possible mechanism for the inhibition
of angiogeneses. A targeted approach could possibly allow
the breakdown of speciﬁc vasculature. In addition to this
study, another possible inhibitor of both FGF and VEGF
was examined. A plasma glycoprotein, Beta-2 glycoprotein-
1, was found to have inhibitory eﬀects on Human Umbilical
Vein Endothelial Cells (HUVEC) proliferation, migration,
and tubule formation in a dose-dependent manner [96].
This was accomplished by the downregulation of VEGFR-
2, the main mediator of angiogenic signals from VEGF
which is also activated by bFGF [96]. When low doses
of Beta-2 glycoprotein-1 were applied, HUVEC prolifer-
ation was decreased by 11.5% [96]. As this dosage was
increased, proliferation continued to decrease until the high-
est dose, which displayed a 68.9% reduction in proliferation
[96].
2.3.3.TieReceptors. TheTiereceptorsareafamilyoftyrosine
kinases expressed by ECs that mimic the behavior of VEGF
receptors [33, 97]. To date, Tie1 and Tie2 have been iden-
tiﬁed, and their mechanisms of action studied. Genetically
altered mice bred without either receptor underwent normal
vasculogenesis,buttheirECslackednormalintegritycausing
the mice to die from widespread edema and hemorrhage due
to a lack of adequate angiogeneses [98]. While both Tie1 and
Tie2 receptors are important for vascular integrity [32, 99,
100], only Tie2 appears to be vital to vascular sprouting and
branching occurring during angiogeneses [3].
Tie Receptor inhibitors have recently been produced in
the lab. A research group has developed several Tie inhibitors
and tested them in vitro to ﬁnd one with the best selectivity,
potency, and pharmacokinetic parameters [101]. Although
preliminary studies for Tie2 inhibitors have begun, further
animal and possibly clinical trials still remain.
2.3.4. Angiopoietins. Angiopoietins are protein growth fac-
tors that act as ligands for the Tie Receptors on ECs
[21]. There are two important angiopoietins that play a
role in angiogeneses, Ang-1 and Ang-2. Ang-1 is a well-
characterized regulator of angiogeneses. It is an important
agonist of and ligand for Tie2 receptors [32]. Experiments
have shown that mice that lack Ang-1 or Tie2 receptors will
develop normal primary vasculature, but will eventually die
because vascular remodeling was never completed [32, 102].
The interaction between Ang-1 and Tie2 is important in
angiogeneses as it helps recruit pericytes to newly created
blood vessels, increasing the stability of the new vasculature
and making it less permeable [32]. Ang-1 also helps induce
formation of capillary sprouts and promote survival of ECs
[21]. Overexpression of Ang-1 in transgenic mice led to a
greater number of blood vessels, with larger diameters, and
more vascular branches [34], illustrating the important role
Ang-1 plays in vascular sprout formation.
Preliminary studies have been completed to determine
whether Ang-1 inhibitors would be an eﬀective method
for reducing levels of angiogeneses. A recombinant human
Ang-1 antisense strand was made and used to inhibit
Ang-1 expression levels in mice with implanted tumor
tissue [103]. Microvascular density in the antisense Ang-1-
treated group averaged 6.02vessels/mm in implanted tumor
tissue while the group not receiving the antisense strand
averaged 8.44vessels/mm in the implanted tumor tissue
[103]. The group concluded that although Ang-1 inhibitors
may help reduce the levels of angiogeneses, it was unlikely
that Ang-1 inhibitors alone would be an eﬀective method
to inhibit pathogenic angiogeneses. The study suggested that
several angiogeneses modulators would need to be inhibited
simultaneously to have a noticeable eﬀect on angiogeneses
[103].
The role of Ang-2 is more complicated than that of
Ang-1. It appears that Ang-2 is at least a partial antagonist
of Tie2, resulting in pericyte loss [35]. The result of this
pericyte loss is destabilization of the blood vessel. Under
normal conditions this helps prevent excessive angiogeneses.
However, the destabilization also allows newly formed blood8 Journal of Oncology
vessels to be more plastic. These destabilized vessels show
increased endothelial sprouting and tube formation in
the presence of VEGF [36]. This fact has made Ang-2
blockers an important area of study for tumor angiogeneses
inhibition. A recent study created Ang-2-selective peptide-Fc
fusion proteins and antibodies; this enabled a controlled
pharmacologicalinactivationofendogenousAng-2,allowing
the group to study Ang-2 inactivation without using the
lethal knockout approach [104]. The use of these inhibitors
demonstrated tumor inhibition in mice as well as corneal
angiogeneses inhibition in rats [104]. Although the study
demonstrated the properties of Ang-2 in vivo and gave
therapeutic possibilities to Ang-2 inhibitors, many questions
still remain. How Ang-2 inhibition blocks EC proliferation is
still not completely understood. In addition, it is unknown if
inhibition of both Ang-1 and Ang-2 would further reduce
angiogeneses or if blocking one will oﬀset the inhibition
of the other. Additionally, these studies have only been
completed using animal models, and we can only hope that
a similar eﬀect will be seen in humans.
Despite the current problems understanding Ang-2, the
selective inhibition of Ang-2 could have a very high clinical
value. Studies have demonstrated that Ang-2 upregulation is
seen in several diseases that involve pathogenic angiogeneses
including cancer, macular degeneration, rheumatoid arthri-
tis, osteoarthritis, and psoriasis [105–107]. One recent study
found that mRNA levels of Ang-2 in metastatic liver cells
and lymph nodes are between 1.5 and 2 times greater than
normal levels [108].
2.3.5. Platelet-Derived Growth Factor. PDGF is another
important signaling molecule with several diﬀerent roles in
angiogeneses. Although originally puriﬁed from platelets,
it has also been identiﬁed in ﬁbroblasts, astrocytes, ECs,
and several other cell types [38]. To date, both hetero
and homodimeric versions of PDGF (PDGF-AA, -BB, or
-AB) have been studied. Capillary ECs express PDGF-BB
receptors, and when the receptors are stimulated, increased
DNA synthesis and angiogenic sprouting can be seen in vitro
(Figure 3)[ 38]. Although pericytes are initially recruited
to growing microvessels independently of PDGF, pericyte
proliferation and migration at a growing blood vessel is
enhanced by interaction with PDGF [109]. Mice bred
without PDGF-BB or its receptor exhibited a large increase
in the permeability of their blood vessels and died prenatally
[110].TheinteractionofPDGFwithitsreceptoronpericytes
increases the expression of Ang-1. This increase in Ang-
1 leads to a signaling cascade that helps establish the
interaction between pericytes and ECs [97]. This interaction
is important for maintaining the stability of newly formed
capillary walls [3], a vital part of new blood vessel formation.
It has been hypothesized that blocking PDGF from
interacting with its receptor will reduce the stability of the
growing capillaries rendering them incapable of delivering
nutrients to the cancer cells [111]. Inhibition of PDGF
has been attempted with compounds such as CP-673,451
[111]. Rat glioblastomas treated with CP-673,451 showed a
47% decrease in microvascular density and a 55% decrease
in tumor growth. Although a decrease in tumor growth
and angiogeneses has occurred through the treatment of
cancers with CP-673,451 during in vitro and in vivo
animal studies, clinical trials have not been performed to
demonstrate its eﬃcacy in humans. Another recent study
indicatedthatlycopene,acarotenoidfoundintomatoes,may
inhibit PDGF-BB-induced signaling [112] reducing levels of
unwanted angiogeneses.
2.3.6. Transforming Growth Factor-Beta. Transforming
Growth Factor-Betas (TFG-β) are a family of homodimeric
cytokines that help control many diﬀerent processes in
the body, including angiogeneses. TGF-β’s are normally
found in the ECM of many diﬀerent cells types [113, 114].
Within the microvasculature, both ECs and pericytes
produce and display receptors for TGF-β [99], illustrating
the variety of cells capable TGF-β expression. To date, both
pro- and antiangiogenic properties have been ascribed to
TGF-β. At low doses TGF-β helps initiate the angiogenic
switch by upregulating angiogenic factors and proteinases.
However, at high doses TGF-β inhibits EC growth, promotes
basement membrane reformation, and stimulates SMC’s
diﬀerentiation and recruitment [39]. Genetic studies in mice
have shown that the loss of TGF-β leads to leaky vessels
lacking structural integrity leading to premature death
[42]. Stimulation of angiogeneses through TGF-β is mostly
via indirect mechanisms. TGF-β signals inﬂammatory
mediators to the site of angiogeneses, where inﬂammatory
cells release proangiogenic factors such as VEGF, FGF, and
PDGF [40, 41].
Recent phase I/II clinical trials attempting to use TGF-β
inhibitors have been completed. These studies employed
aT G F - β antisense oligonucleotide, termed AP12009, as a
treatmentforpatients withmalignantgliomas [115].Despite
the late stage of the glioma in the patient population,
positive eﬃcacy results were observed. Two of the 24 patients
saw complete remission of their disease after treatment
and remained cancer free 4.5 years after completion of
the trial [115]. Seven of the 24 patients also found their
disease stabilized after beginning treatment, a larger number
compared to controls in other clinical trials [115]. In
addition, the median survival time of the AP12009-treated
patients was longer than the controls reported by recent
literature [115]. After the initial positive results of this trial,
a Phase IIB trial was initiated and is still ongoing [115].
These results indicate that the targeted inhibition of TGF-β
may provide an excellent mechanism to reduce unwanted
angiogeneses in a variety of diseases.
2.3.7. Integrins. Integrins are heterodimeric cell surface
receptors for ECM proteins that also play a role in cell-cell
attachment. They contain various α-and β-subunits, with
over 20 diﬀerent combinations of subunits known. Integrins
are important regulators for many diﬀerent cell processes
including both vasculogenesis and angiogeneses [116].
Of the integrins, αVβ3 is one of the most extensively
studied, and has an important role in angiogeneses. It binds
and activates MMP-2 at the tips of growing blood vesselsJournal of Oncology 9
to help break down the ECM [43]. Integrin αVβ3 shows
increased expression in vitro when exposed to VEGF [27]
and bFGF [117]. Cell attachment, spreading, and migration
are all regulated by integrin αVβ3i nv i t r o[ 44]. Angiogenic
blood vessels near granulation tissue showed much greater
levels of αVβ3 than vessels in uninjured normal skin [45].
Duringwoundrepair,αVβ3islocalizedtotheECsattheends
of the growing vessels [46]. Anti-αVβ3 monoclonal antibod-
ies reduce bFGF-stimulated angiogeneses, demonstrating an
important relationship between the two proteins [47].
Several other integrins have also been implicated in
angiogeneses. Inhibition of integrin αVβ5 hindered angio-
geneses stimulated by VEGF [47]. Abs to collagen receptor
integrins (α1β1a n dα2β1) also reduced VEGF-mediated
angiogeneses[75].Avarietyofintegrinsplayimportantroles
in angiogeneses including EC adhesion to ECM, protease
localization, and increased EC survival [3]. This diversity
s u g g e s t san u m b e ro fd i ﬀerent integrins; each plays a distinct
role that uniquely contributes to the process of angiogeneses.
There are currently three classes of integrin inhibitors
in preclinical and clinical trials. Some of these include
a synthetic peptide Cilengitide (a αVβ3/αVβ5 inhibitor),
a monoclonal Ab Abergin (a αVβ3 antagonist), and a
peptidomimetic compound S247 (a αVβ3/αVβ5) antagonist
[118]. Phase I trials using Vitaxin (similar to Abergin) were
unsuccessful in reducing tumor growth [119]. A second
generation Phase II trial which altered Vitaxin to give it
greater aﬃnity for αVβ3 also failed to reduce tumor growth
[120, 121]. Phase I and II trials with Cilengitide have also
been completed. Although some antitumor eﬀects in the
treatment of gliomas were seen with Cilengitide, the study
concluded that its action appeared to be antitumor cell
speciﬁc as opposed to angiostatic [118]. Trials in other
cancer patients failed to show any reduction in tumor
load using Cilengitide [122, 123]. The low eﬃcacy of the
αVβ3/αVβ5 antagonists demonstrates that the mechanistic
understanding of integrins in angiogeneses is not yet fully
understood.Atthistime,antagonistsforαVβ3orαVβ5alone
do not appear to prevent angiogeneses, and other strategies
need to be examined. Currently, integrin inhibitors for α2β1
[118, 124, 125]a n dα5β1[ 118, 126] are being tested in phase
I and phase II clinical trials.
2.3.8. Cadherins. Cadherins are a class of calcium-binding
transmembrane proteins that play an important role in
cell-cell interactions. Several studies have underlined the
important role of one particular cadherin, the vascu-
lar endothelial (VE) cadherin, in neovascularization. VE-
cadherins are localized exclusively to the adherens junctions
in ECs [127]. It has been suggested that VE-cadherins are
important in regulating the passage of various molecules
across the endothelium [28, 29]. In addition, VE-cadherin
plays an important role in mediating EC growth through
contact inhibition [48]. Mice deﬁcient in VE-Cadherin
showed extreme vascular abnormalities including dimin-
ished branching and sprouting, as well as disconnected ECs
[48]. The vascular problems continued to progress until the
vessels ﬁnally regressed or disintegrated [49]. This is thought
to occur because the VE-cadherins establish EC junctional
stability in the vessel walls. The cadherins also enhance EC
survival by increasing the transmission of the antiapoptotic
signal of VEGF [49]. Therefore, despite VE-cadherins non-
existent role in vasculogenesis, it is vital to the maturation of
blood vessels associated with angiogeneses [38].
Inhibition of VE-cadherins to prevent angiogeneses
has been examined in several diﬀerent animal models.
Monoclonal Abs designed to recognize certain sections of
extracellular repeats found in active VE-cadherins have
been designed [128]. These Abs prevented EC junctional
assembly and induced the disassembly of already existing EC
junctions in vitro, abilities that could help prevent unwanted
angiogeneses [128]. Although these original Abs were found
to have some inhibitory eﬀects on angiogeneses at low doses,
signiﬁcant vascular permeability was found in the heart and
lungs of the mice at moderate to high doses, illustrating
toxic side eﬀects of the Abs [129, 130]. Since these original
studies, other monoclonal Abs have been developed that do
notexhibitthevascularpermeabilityproblemsoftheoriginal
version; these include BV14 and E4G10 [131, 132]. It is
currently hypothesized that these second-generation mon-
oclonal Abs will be eﬀective because angiogenic junctions
are weaker and contain diﬀerent epitopes which are open to
monoclonal Ab targeting [133] .O t h e rg r o u p sh a v ef o c u s e d
on the gene sequence of VE-cadherins, which may allow
researcherstoproducemorespeciﬁcmonoclonalAbsforVE-
cadherins and prevent unwanted angiogeneses [134].
VE-cadherins role in retinal neovascularization was
also recently examined in mice. A group induced retinal
neovascularization in newborn mice by exposure to oxygen
[135]. Some of the mice were then treated with a VE-
cadherin antagonist while others were treated with a control
peptide. The mice treated with the VE-cadherin antagonist
saw signiﬁcantly reduced retinal angiogeneses compared to
the control group [135]. In addition, the group treated
with the antagonist had reduced levels of EC migration and
proliferation as well as suppressed tubule formation from
ECs [135]. As studies designed to better comprehend VE-
cadherins role in angiogeneses have been completed, it has
become clear that the role of cadherins in the angiogenic
pathway is larger than just their adhesive activity. The
ability of VE-cadherins to interact with various signaling
molecules suggests that it has a role in EC growth, migration,
survival, and morphogenesis [133]. Although VE-cadherin
inhibitors alone are not capable of suppressing angiogeneses
at this time, combining a VE-cadherin inhibitor with other
inhibitors of angiogeneses may provide more complete
suppression.
2.3.9. Endoglin. Endoglin (Eng, CD-105) is a homodimeric
cellsurfaceglycoproteinthatservesasacoreceptorforTGF-β
[136]. Eng is found on proliferating ECs and also serves as an
EPC marker [137]. It has been observed that Eng expression
is greatly increased during angiogeneses and inﬂammation
[138]. Studies have shown that Eng can regulate TGF-β,b u t
the mechanism remains unknown [139]. With this function
in mind, researchers have investigated the use of anti-Eng-
based therapies in several diﬀerent forms of cancer with10 Journal of Oncology
the hopes of preventing tumor-based angiogeneses. Early in
vitro studies using anti-Eng mAbs in the presence of human
ECs showed that the mAbs greatly reduced growth of the
ECs [140]. Following this work, in vivo studies showed that
injections of anti-Eng mAbs into mice with colon or breast
cancer xenografts demonstrated signiﬁcant reductions in
tumor size and had much greater survival rates than controls
[141, 142].
The United States FDA approved a multicenter phase I
clinical trial in 2008 using a naked anti-Eng mAB (TRC105)
in patients with advanced and/or metastatic cancers [143].
Preliminary results from this trial have suggested clinical
activity and tolerability of the mAb TRC105 in 17 patients
[143]. As we await further results, no conclusive decision can
be made about the clinical value of anti-Eng mAbs, though
there does appear a reason for optimism. While this trial
continues, several other groups have suggested conjugating
the anti-Eng mABs with toxic molecules to ensure that the
targeted ECs are killed. This model has had success in mice
with breast cancer without any measurable toxicity [144]. In
either case, Eng has been shown to be an important regulator
ofangiogenesesandabetterunderstandingofitsmechanistic
course of action may help the drug design process in the
future.
2.3.10. Additional Factors. In addition to the factors men-
tioned above, many others have been shown to play impor-
tantrolesinangiogeneses,buttheireﬀectsonthevasculature
are not as widespread or as understood as the previously
mentioned factors. An example of this is Tumor Necrosis
Factor-α (TNF-α), a cytokine usually secreted by activated
macrophages. TNF-α has been shown to help stimulate
angiogeneses in vivo [50] and stimulate EC tube formation
in vitro [51]. Transforming Growth Factor-α (TGF-α)i s
another cytokine secreted by macrophages and is capable
of stimulating angiogeneses and EC proliferation in vivo
[52]; however its role is still not completely understood.
Angiogenin is another small polypeptide whose role in
angiogeneses is still being investigated. It promotes angio-
geneses in chorioallantoic membrane and rabbit cornea
[53], but it is not mitogenic or chemotactic for ECs in
vitro [53]. Angiogenin helps support EC adhesion and
spreading in vitro [54]; however, its levels of synthesis are
inconsistent with the timing of neovascularization in vivo
[145]. Angiotropin is a polyribonucleopeptide originally
isolated from peripheral monocytes [55]. Angiotropin is
able to randomly induce capillary EC migration and tube
formation in rabbit skin [55] and may trigger proliferative
reactions in wound healing by activating microvascular ECs
[38].
2.4. Angiogeneses Inhibitors: Current Research and
Clinical Implications
2.4.1. Angiostatin. Angiostatin is a 38kDa internal fragment
of plasminogen that displays inhibitory eﬀects against tumor
angiogeneses [146]. When plasminogen is in the vicinity
of an implanted and/or primary tumor, it is cleaved by
an unknown protease; a product of this cleavage is the
antiangiogenic protein angiostatin [5, 147]. Research groups
have shown that the endogenous protein is capable of
inhibiting the growth of distant metastases [147, 148].
Experiments with angiostatin demonstrated that its
activity leads to several diﬀerent physiological results. As
mentioned, angiostatin was shown to reduce the growth of
remote metastasis [147]. This is accomplished by increasing
the rate of apoptosis in metastatic tumors [149]. Apoptosis
is increased because angiostatin attacks the energy system
of the metastatic tissue by inhibiting ATP synthase F1F0,
leading to caspase-mediated apoptosis [149, 150]. Another
eﬀect of activated angiostatin is the inhibition of capillary
endothelial growth in vitro [151]. Mice with gliomas and
melanomas experienced greatly reduced tumor growth and
neovascularization when they were genetically engineered to
expressangiostatin[152,153].Theactivityofangiostatinwas
also examined on a global level using microarray techniques.
A total of 189 genes had their expression levels altered
with treatment of angiostatin. Most of these genes were
involved in growth, apoptosis, and migration of ECs, as well
as inﬂammation [6, 154], demonstrating the wide range of
eﬀects that angiostatin has within the body.
To date, several clinical trials have tested the eﬃcacy
of angiostatin as a treatment for several forms of cancer.
Subcutaneous injections of recombinant human angiostatin
showed little to no toxicity in phase I clinical trials [155].
Phase II trials using angiostatin in combination with both
paclitaxel and carboplatin have been completed in non-
small-cell lung cancer (NSCLC) patients [156]. The response
rate of the combinational therapy was higher than previous
studies using the chemotherapy alone [156]. The group
reported thatthe overallresponse rateto the combined treat-
ment was 39.1%, another 39.1% of the patients remained
stable, while the last 21.7% of the patients saw their disease
progress [156]. Although the group did see improved rates
of treatment, they fell below the expected levels. Several
groups are working on alternate methods of administering
angiostatin to increase its success as a treatment. Experi-
ments using intravenous administration of angiostatin genes
complexed to cationic liposomes are ongoing [157].
2.4.2.Endostatin. Endostatinisanangiostatic20-kDinternal
fragment of the carboxy terminus of collagen XVIII [151],
an important proteoglycan in basement membranes. It was
originally discovered in the blood and urine of tumor-
bearing mice [151]. Two of the enzymes responsible for the
release of endostatin include elastase [158] and cathepsin L
[159]. Endostatin interacts with many diﬀerent cell surface
proteins including the integrins (α5β1 and to an extent also
αVβ3a n dαVβ5) [151] and several glycpians [160]. These
interactions result in altered EC adhesion and migration [6].
In vitro, endostatin inhibits EC migration, proliferation,
and tube formation [151], three key aspects of angiogeneses.
Inhibitionofangiogenesesviaendostatinleadstoareduction
o ft u m o rg r o wt hi nv i v o[ 161]. It appears that this inhibition
is partially accomplished by reducing the expression of
VEGF [162]. Endostatin also has the ability to block existingJournal of Oncology 11
VEGF from interacting with its receptor VEGFR-2 [163].
Endostatin reduces EC proliferation by arresting the EC cell
cycle through the downregulation of cyclin-D1 promoter
transcriptional activity [164]. As a result, the cell is unable
to progress through the G1/S transition. Recent studies
have also shown that endostatin disturbs the survival/death
balance via activation of the proapoptotic pathway through
the induction of caspase-9 activation [165]. These pathways
induction is due to the endostatin-led decrease of the anti-
apoptotic proteins Bcl-2, Bcl-Xl, and Bad [165]. Gene array
and proteonomic analysis have given insight into the vast
numberofgenesthatcanbeaﬀectedbyendostatintreatment
in human dermal microvascular ECs. Approximately 12%
of the 74,834 genes represented on the microarray chip had
altered expression levels when treated with endostatin [166].
Both angiostatin and endostatin cause apoptotic pathway
activation [166]. However, the identity and number of genes
regulated by endostatin diﬀer from angiostatin, suggesting
alternative pathways of action.
Evidence for endostatin’s importance can been seen by
studying individuals with Down Syndrome. People with
D o w nS y n d r o m eh a v eat h i r dc o p yo fc o l l a g e nX V I I Id u e
to a trisomy of chromosome 21. These individuals tend to
havea1.6–2foldelevationofendostatinlevels[167]andhave
greatly reduced levels of malignant tumors (except testicular
cancer and megakaryocytic leukemia) [168], atherosclerosis
[169], and diabetic retinopathy due to neovascularization
[170]. These three diseases are all angiogeneses-dependent
[5], and showcase the important role that endostatin may
play in inhibiting unwanted pathogenic angiogeneses in
humans.
Endostatin is currently being analyzed for therapeutic
potential in several forms of cancer. Using animal studies,
a group recently demonstrated that it may be used as a
possible treatment to boost the post-operative prognosis
of osteosarcoma patients [171]. The study was designed to
determine whether antiangiogenic treatment could help pre-
vent the progression of pulmonary metastasis, a secondary
problem often associated with postoperative osteosarcoma
[171].Thegroupinjectedanadenovirusencodingendostatin
vector (Ad5CMV-mEnd) two weeks after tumor inoculation
[171]. The group found statistically signiﬁcant diﬀerences
in the size and prevalence of pulmonary metastasis between
t h ec o n t r o la n dt r e a t m e n tg r o u p st w ow e e k sa f t e rt h e
administration of the vector [171].
A recently completed animal study investigated the use
of an endostatin-angiostatin fusion protein in Renal Cell
Carcinomas (RCCs). The group tested the fusion pro-
tein’s ability to inhibit tumor angiogeneses, tumor growth,
and metastasis [172]. All animals underwent postmortem
histopathological analysis of the liver, kidney, lung, spleen,
and brain to determine levels of metastasis. The mice
treated with the angiostatin-endostatin fusion protein had
a 97% primary tumor growth reduction compared to the
controls. In vivo tumor vascular imaging showed that the
fusion-treated group had fewer blood vessels, and decreased
lumen diameter [172]. These results indicate that sustained
angiostatin-endostatin gene therapy may provide a novel
treatment method for metastatic RCCs [172].
Clinical trials using endostatin for the treatment of
several types of cancer are ongoing. Phase I clinical tri-
als showed that endostatin is well tolerated by patients,
but its antitumoral activity was minimal at best [173–
175]. A multicenter phase II study of recombinant human
endostatin use in carcinoid neuroendocrine tumors and
pancreatic neuroendocrine tumors was recently completed.
The endostatin vector was given subcutaneously to 42
patientswiththeadvancedformofeitherdisease[176].None
of these patients experienced signiﬁcant toxicity; however
they did not demonstrate a clinically relevant radiological
responseeither[176].Eightypercentofthepatientsreceiving
treatment experienced disease stabilization, while the other
20% had further disease progression [176]. Although the
study found minimal beneﬁt from the treatment, the group
admitted that the optimal therapeutic dosage and form
of administration are still unknown [176]. In addition,
it has been suggested that adding endostatin to current
chemotherapeutic strategies may enhance the eﬃcacy of
the treatment for carcinoid and pancreatic neuroendocrine
tumors [176]. Another group examined the use of novel
recombinant endothelial endostatin (YH-16) also known
as “endostar,” for advanced NSCLC patients in a phase
III trial [177]. The phase III trial treated one group of
patients with endostar in combination with vinorelbine and
cisplatin, while the other group of patients only received
only vinorelbine and cisplatin [177]. The group that received
endostar saw a response rate of 35.4%, while the group
that received the chemotherapeutics alone saw response
rates of only 19.5%. The median time to progression was
6.3 months in the endostar-treated group compared to 3.6
months in the control group. The clinical beneﬁt rates
for the chemotherapeutic and endostar-treated group were
73.3% while the rates for group receiving vinorelbine and
cisplatin alone were 64% [177]. Overall, the study found
that the addition of endostar to the vinorelbine and cisplatin
treatment resulted in signiﬁcant and clinically meaningful
improvement compared to the vinorelbine and cisplatin
treatment alone.
2.4.3. Tumstatin. Degradation of type IV collagen releases a
28kDa fragment known as tumstatin, a compound that also
displays antiangiogenic properties [178]. Tumstatin binds
the αVβ3 integrin, which results in G1 arrest and the
induction of EC apoptosis [179]. Mice models have shown
that exogenous tumstatin is able to inhibit the growth of
tumors [179]. In addition, tumstatin-deﬁcient mice had a
much greater microvessel density near implanted murine
tumors, and the mice had a 300% increase in overall tumor
growth [5].
Animal studies determining the viability of tumstatin
as an antiangiogenic-drug have been and continue to be
completed. Tumstatin treated mice with teratocarcinomas
showedovera90%reductionintumorsizecomparedtocon-
trols [180]. The same group also examined a combination
of anti-VEGF (Avastin) and tumstatin treatment compared
to the tumstatin treatment alone. The animals receiving
the combination treatment saw a statistically signiﬁcant
reduction in tumor growth when compared to the tumstatin12 Journal of Oncology
aloneoraplacebo[180].Theseﬁndingsdemonstratedstrong
preclinical evidence for a future treatment of cancer with an
anti-VEGF Ab alongside a tumstatin peptide [180]. Another
recently completed animal study examined gene delivery of a
tumstatin fragment into hepatocellular carcinomas (HCCs)
[181]. In vivo intratumoral injection of the tumstatin
fragment (pSecTag2B-tum-1) greatly diminished the growth
of preestablished human HCCs [181]. In addition, there was
a decrease in the amount of CD-34 positive vessels in the
tumor [181].
2.4.4. Platelet Factor-4. Platelet Factor-4 (PF-4) is a chemok-
ine naturally secreted by platelets that normally promotes
blood coagulation. In addition to this role, PF-4 is also
known to be an inhibitor of angiogeneses. PF-4 is secreted
from the alpha-granules of activated platelets and binds
with high aﬃnity to heparin-like glycosaminoglycans on the
surface on ECs blocking them from further activity [6].
Studies have also shown that PF-4 blocks the upregulation
of MMP-1 and MMP-3, inhibiting EC migration [182].
Finally, PF-4 is also capable of inhibiting the EC cell cycle
by impairing pRB phosphorylation [183].
Despite the antiangiogenic and antitumoral eﬀects of
PF-4 in murine human tumor implant models [184], PF-
4h a sn o tp r o v e nt ob ea ne ﬀective treatment for human
cancers [185] .Th ee a rl yf a i l u r eo fP F - 4a sam o n o t h e ra pe u ti c
treatmentledresearcherstoexaminediﬀerentapproachesfor
the use of PF-4 as an angiostatic agent. Recently, researchers
produced a novel peptide containing the active fragment of
PF-4 along with vasostatin, an inhibitor of EC proliferation
[186]. This peptide was examined as a potential angiostatic
agent in chick embryos. In vivo neovascular growth was
compared between a group receiving the novel peptide,
a group only receiving vasostatin, another receiving PF-4
alone, as well as a control. The chick embryos receiving
the novel peptide showed a statistically signiﬁcant reduction
in angiogeneses when compared to the other groups [186].
Although the study was only completed in animals, it
demonstrates another possible drug that may be used to
inhibit tumor angiogeneses.
2.4.5. Thrombospondin. Thrombospondin-1 (TSP-1), the
ﬁrst naturally occurring angiostatic protein discovered, is a
multidomain matrix glycoprotein that has been shown to
be a natural inhibitor of neovascularization [187]. Unlike
previous angiostatic agents discussed, TSP-1 is a native, full-
length protein. TSP-1 is stored in α-granules of platelets,
where it is complexed with TGFβ1[ 188]. When released
from the platelets and free from TGFβ1, TSP-1 inhibits the
migration of ECs [189] and induces EC apoptosis [190]. To
slow migration, TSP-1 binds to EC surface receptors capable
of promoting promigratory signals [189]. The induction of
apoptosis in ECs is associated with TSP-1’s ability to alter
the concentrations of several important apoptotic factors.
TSP-1 upregulates Bax, downregulates Bcl-2, and activates
the caspase-3 intrinsic pathway, leading to programmed
EC death [191]. Other experiments have shown that mice
depleted of TSP-1 saw a 250%–300% increase in tumor
growth rate when implanted with murine tumors [1].
Microvessel density was also increased near the tumor in
these mice [5].
A phase I clinical trial using ABT-510, an angiogenic
inhibitor derived fromTSP-1, has been completed. This drug
wasdeliveredsubcutaneouslyinpatientswithadvancedsolid
malignancies. Although the phase I trial was not designed
to test eﬃcacy, 6 of the 39 patients saw disease stabilization
after the treatment [192]. The toxicity eﬀects associated
with ABT-510 were minimal and deemed safe for future
trials[192].TheuseofABT-510alongsidechemotherapeutic
agents has also been examined. A phase I clinical trial
investigated the use of ABT-510 with gemcitabine-cisplatin
chemotherapyinpatientswithsolidtumors[193].Thisstudy
found no clinically signiﬁcant pharmacokinetic interactions
between the combined drugs. Despite the low doses, 3 of
the 12 patients tested saw a partial response with the drug
treatment [193]. Another phase I trial examined the toxicity
proﬁle of ABT-510 along with the chemotherapeutics 5-
ﬂuorouracil and leucovorin [194]. Minimal toxicity was
found by combining the drugs, and 4 of the 12 patients
had tumor stabilization posttreatment [194]. Both of the
combined phase I trials stated that the optimal dosage
for ABT-510 has not been established yet, and determin-
ing these values would be important in future clinical
trials.
2.4.6. Tissue Inhibitors of Metalloproteinases. Tissue Inhib-
itorsofMetalloproteinases(TIMPs)areafamilyofproteases,
derived from cartilage, which inhibit MMPs. As previously
mentioned, MMPs play an integral role in the initiation of
angiogeneses. They are responsible for EC basement mem-
brane degradation and EC remodeling [3, 67]. The newly
formed ECM developed by MMPs during the angiogenic
response provides a scaﬀold for ECs to adhere, migrate,
and form tubes for nutrient delivery. The inhibition of
MMPs by TIMPs reduces the angiogenic capacity of ECs
[195, 196]. High levels of TIMP-1 greatly inhibit migration
of ECs through gelatin in vitro [197]. The invasive poten-
tial, growth, and neovascularization of metastatic murine
melanoma cells were inhibited in vivo when transfected with
TIMP-2 [195].
TheroleofTIMP-3intumorangiogeneseswasexamined
using mice models. The study found that TIMP-3 treatment
of mice with lung cancer led to reduced angiogeneses in
vivo through the inhibition of the VEGF-VEGFR-2 signaling
pathway and the induction of EC-apoptosis [198]. The
inhibition of this pathway and the EC associated death
are in part due to the inhibition of MMP-2 by TIMP-3
[198]. Another study investigated the use of TIMP-1 gene
transfer through an adenovirus as a way to treat established
gastric cancer in nude mice. Compared to controls, mice
transfected with TIMP-1 gene saw a signiﬁcant reduction
in the mean number of tumor vessels [199]. Although
the exact mechanism of TIMPs inhibition of cancer pro-
gression remains unclear, TIMPs should still be considered
for therapeutic trials because of their success in animal
models.Journal of Oncology 13
2.4.7. Interleukins. Interleukins (ILs) are a group of
cytokines that are released by leukocytes and control a
wide range of biological activities. A few of these ILs have
been shown to aﬀect the growth of blood vessels [200].
The ability to either enhance or suppress angiogeneses is
based on a Glu-Leu-Arg (ELR) motif at the NH2 terminus.
IL-8 possesses this sequence (discussed later), and therefore
enhances angiogeneses, while IL-4 does not contain the
motif, and is an inhibitor of angiogeneses [200].
IL-4 acts as an inhibitor of tumor growth [201], but its
mechanism of action likely varies with diﬀerent tumor cells.
For example, IL-4 is thought to directly inhibit proliferation
of cells from cancers such as colon tumors, head and neck
tumors, and glioblastomas [202], while in other cases it is
thoughttoinduceahostimmuneresponseagainstthetumor
c e l l ss u c ha si nB - c e l ll y m p h o m a sa n dm e l a n o m a s[ 203].
There is also evidence that IL-4 inhibits neovascularization,
thus inhibiting tumor growth. In vitro, IL-4 inhibits migra-
tion of ECs towards bFGF. In vivo, IL-4 has been shown to
inhibit neovascularization in rat corneas that should have
been induced by the high concentration of bFGF present
[204]. These experiments demonstrate that IL-4-mediated
suppression of tumor growth may be due to IL-4s ability
to inhibit angiogenic processes. Other noncancer-related
animal studies have shown IL-4’s antiangiogenic capabilities
in vivo. One such study examined rats with adjuvant-
induced arthritis. One set of animals received an adenovirus
capable of producing IL-4, another group received a control
virus without the IL-4 producing capabilities, and the last
received a saline injection [205]. The group treated with
the IL-4 producing adenovirus saw a statistically signiﬁcant
r e d u c t i o ni nb l o o dv e s s e lg r o w t h[ 205]. The reduction
in angiogeneses from the IL-4 treatment appears to be
associated with a change in the pro- and antiangiogenic
cytokine levels [205]. Although the study was designed
to study inﬂammatory arthritis, knowledge gained about
IL-4 could be used for the treatment of cancer in the
future.
2.4.8. Interferons(IFNs). Interferons(IFNs) belong to a large
familyofsecretedglycoproteinsknownascytokines.Theyare
p r o d u c e da n ds e c r e t e db yaw i d ev a r i e t yo fi m m u n e - r e l a t e d
cells and IFN-α has been shown to inhibit angiogeneses in
vivo [206]. It is thought that both IFN-α and IFN-β are
able to inhibit angiogeneses by repressing bFGF mRNA and
protein levels [207]. In addition to the downregulation of
key angiogeneses signaling factors, IFN-α also inhibits the
m i g r a t i o no fE Cc e l l si nv i v o[ 208].
Several clinical trials have been performed investigat-
ing the administration of IFN-α in combination with
chemotherapeuticsindiﬀerentformsofcancer.Manystudies
have used PEG IFN-α,af o r mo fI F N - α that has been
modiﬁed to have a longer half-life and thus have a greater
opportunity to reduce angiogeneses [209]. A phase I trial
completed tested the eﬀect of subcutaneous injections of
PEG IFN-αand recombinantIL-2in patients withmetastatic
RCC [210]. Minimum toxicity was found at most levels, and
an unsafe level of the drug combination was determined.
Of the 34 patients in the study, 15% saw a partial response,
68% had disease stabilization, and 18% had their disease
continue to progress. Overall, the median survival was 31.9
months for patients treated and their median progression-
free survival was 9.0 months [210]. Both the median survival
time and the median progression-free survival time were
slightly greater than the average control reported in the
literature [210]. It was determined from this study, though,
that IFN-α alone or in combination with IL-2 is not the
optimal treatment of RCCs. The group did suspect that the
use of IFN-α in combination with Avastin (a monoclonal
Ab that targets VEGF) may provide a better treatment for
RCC [210]. This theory was tested in a clinical trial using
patients who also had metastatic RCCs. They reported that
the median progression-free survival in patients receiving
the combined Avastin and IFN-α treatment was double
that of patients only receiving IFN-α and a placebo [211].
The combined therapy also showed improvement in overall
response rate from 13% in the IFN-α alone group to 32% in
the combined treatment arm of the study [211]. A clinical
beneﬁt was seen in 79% of the patients receiving combined
treatment versus 65% in the IFN-α alone treatment group
[211]. Lastly, the median duration of tumor response was
13.5 months in the combined drug group while it was only
11.1monthsintheIFN-αonlygroup[211].Aftercompletion
of the study, it was observed that the levels of IFN-α used
were higher than the optimal dosage, and it is likely that
treatment with slightly lower levels of IFN-α would have
seen greater clinical beneﬁt in both groups [211]. The study
determined that the combination therapy was an eﬀective
ﬁrst-line treatment option for metastatic RCC [211], and
further trials should be conducted to determine optimal
dosages.
In addition to metastatic RCCs, clinical trials have also
tested the use of PEG IFN-α as a treatment for metastatic
melanomas.AphaseItrialusingPEGIFN-αdeterminedthat
it was safe and eﬀective in humans [212]. A phase II trial
then investigated the use of Dacarbazine (DTIC) alongside
PEG IFN-α for the treatment of metastatic melanomas. Of
the 25 patients who completed the study, 8% had complete
remission from the treatment, while another 16% had
partial responses [209]. Stable disease was found in 4% of
patients while 72% had their disease progress. Although
the treatment proved that the combinational treatment
was not toxic, the eﬃcacy of the treatment could not be
determined because the study did not compare diﬀerent
regimens of treatment [209]. Despite this, the 24% overall
response rate, including two long-term complete responses,
is promising and warrants more clinical investigation
[209].
2.4.9. Tumor Angiogeneses. Tumors begin as an avascular
mass of host-derived cells that proliferate atypically because
they have lost the ability to control their growth [3]. Tumors
initially survive and thrive on vasculature that is already
available in the surrounding host environment [36]. In
order for tumors to grow beyond 2-3mm3, they need a
continual supply of blood to remove waste and deliver
nutrients [1]. Hypoxia of tumor cells will occur if the
tumor grows beyond the maximum distance of eﬀusion14 Journal of Oncology
from local vessels (around 200μm) [36]. In order to counter
this lack of oxygen, tumor cells will attempt to create new
blood vessels to supply their needs in a mechanism that
closely resembles normal angiogeneses [3]. This process and
several important tumor-derived factors are illustrated in
Figure 3.
The blood vessels formed during tumor-induced angio-
geneses are abnormal. The walls of tumor vessels are usually
made of a combination of both tumor cells and ECs [213].
Functional pericytes are often absent from the peripheral
blood vessels [214], leaving an incomplete basement mem-
brane. This causes those vessels to be especially leaky and
dilated [215]. Recently, it was found that, although the
majority of tumor vasculature does not possess pericytes,
sometumorskeepacoreofbloodvesselsaliveandfunctional
because the vessels are protected by pericytes [216, 217].
This concept emerged from several studies that showed
VEGF signaling inhibition led to a large reduction in tumor
vascularity. However, functional vessels that remained after
treatment were small in diameter and covered with pericytes
[216, 218]. The morphology of these surviving tumor vessels
was very diﬀerent from normal dilated tumor vessels which
are sparsely populated with pericytes [216, 218]. These
observations support the prevailing thought that tumor
vessels lacking pericytes are more vulnerable to anti-VEGF
treatment [218, 219].
Like the normal angiogenic process, tumor angiogeneses
is reliant on VEGF and other angiogenic proteins. Increased
levels of VEGF and its receptor VEGFR-2 have been
observedinmanycancers,includingmetastatichumancolon
carcinomas, where increased levels were shown to directly
increase tumor vascularization [220]. Breast cancer patients
with higher levels of VEGF expression have increased
intratumoral vascularization and a worse prognosis [221].
Experiments with monoclonal Abs against VEGF, or genetic
inactivationofVEGF(orVEGFR-2),havedramaticdecreases
in angiogeneses and neovascularization in several diﬀerent
forms of cancer [83–85]. VEGF is stimulated by the hypoxic
conditions near the central necrotic tissue of solid tumors
[222]. The mechanism of tumor blood vessel growth acti-
vated by VEGF is similar to the normal angiogenic response
to hypoxic conditions. Neovascularization occurs in both
cases to help meet the metabolic needs of cells [2, 3].
In addition to the endovascular stimulation attributed to
VEGF, it can also increase vascular permeability [28, 29, 223,
224], explaining the leaky blood vessels observed in tumors.
VEGF has many important roles in tumor angiogeneses and
therefore its inactivation has often been a target of tumor
therapy.
Ang-2 plays a more important role in tumor angiogene-
ses than it does in normal angiogeneses. As an antagonist
for Ang-1, it is largely responsible for blood vessel destabi-
lization seen in vasculature surrounding tumors. Normally,
destabilization leads to blood vessel breakdown, but in the
presence of VEGF, the vasculature is readily receptive to
VEGF-mediated growth [225]. Ang-2 expression in ECs of
tumor vessels greatly exceeds that of ECs in normal blood
vessels and can be used as an early biomarker of tumor-
induced vascularization [226]. Besides giving the growing
vasculature plasticity in the presence of VEGF, it also plays
an important role in the initial stages of tumor angiogeneses.
During early tumor development, VEGF levels are greatly
reduced, but Ang-2 mRNA levels are high [227]. At this
stage,Ang-2isresponsibleforthedegradationandregression
of blood vessels associated with early stages of tumor
angiogeneses. As the tumor continues to grow in size, it
e v e n t u a l l yr e a c h e sap o i n tw h e r ei tr e q u i r e sm o r en u t r i e n t s ,
thus levels of VEGF rise and new capillary growth can
begin.
FGFwastheﬁrsttumor-derivedfactorfoundtostimulate
neovascularization and EC proliferation in vivo [228]. The
importance of bFGF in tumor angiogeneses was conﬁrmed
by the use of bFGF receptor inhibition in tumor-injected
mice. Inactivation of bFGF receptor led to decreased tumor
growth [228] and blood vessel density [229]. Based on
the time that bFGF is active during tumor angiogeneses,
it has been suggested that bFGF is important in main-
taining this process, as opposed to VEGF which likely
initiates tumor angiogeneses [229]. However, bFGF has
also been shown to help increase VEGF production [230],
upregulate VEGF mRNA in vascular smooth muscle [231],
and increase VEGF receptor density in microvascular ECs
[232].
It was recently discovered that TGF-β signaling behaves
asastrongactivatoroftumorgrowthandmetastasisthrough
stimulation of angiogenic processes [233, 234]. It is believed
that TGF-β expression by neoplastic cells acts to induce
the stromal reaction, which results in the formation of a
reactive stroma microenvironment that is thought to pro-
mote angiogeneses and tumor growth [235]. It has also been
shown that the use of neutralizing Abs against TGF-β leads
to a reduction in the amount of blood vessels surrounding
implanted tumors and greatly inhibits angiogeneses in these
regions [235].
Heparanase is highly reactive 50kDa protein known
to induce tumor angiogeneses [236]. Heparanase is pref-
erentially expressed in both melanoma and carcinoma
[237]. Transfection of both nonmetastatic T lymphoma and
melanoma cell lines with the heparanase gene caused both
cell lines to become highly metastatic in vivo [236]. In
addition, T lymphoma cells transfected with the heparanase
gene saw a considerable increase in neovascularization near
implanted tumors when compared to the nontransfected T
lymphoma cells [236]. Heparanase stimulates angiogeneses
directly by promoting EC invasion and vascular sprouting
[3]. Heparanase also helps release bFGF that is bound to
heparin sulfate at the ECM [236], increasing local bFGF
levels. The increase in the local bFGF concentration is
thought to contribute to the increased neovascularization
measured near implanted tumors.
Interleukin-8, which is produced by macrophages, is
not an important factor in normal angiogeneses. How-
e v e r ,I L - 8a p p e a r st ob eac e n t r a lm e d i a t o ro ft u m o r -
derived angiogeneses. Elevated levels of IL-8 have been
documented in several types of neoplastic tissues [238].
The increased expression of IL-8 correlates with ampli-
ﬁed neovascularization density [238, 239]a sw e l la sa n
increase in tumor growth [238]. Melanoma cells forced toJournal of Oncology 15
continually express IL-8 were highly tumorigenic and had
greater metastatic potential compared with parental and
control transfected cells [238]. An important characteristic
of IL-8 is its ability to increase levels of MMP-2 which
degrades the EC basement membrane and remodels the
ECM, initiating the early phase of tumor angiogeneses
[21]. IL-8-transfected melanoma cells displayed greatly
increased levels of MMP-2, while transfection of identical
melanoma cells with VEGF and bFGF did not aﬀect MMP-
2l e v e l s[ 240, 241] demonstrating that this is an impor-
tant but separate mechanism involved in tumor-induced
angiogeneses.
It is obvious that many diﬀerent factors play an impor-
tant role in tumor angiogeneses. To date, VEGF has been
shown to play the most dominant role, but many other
factors such as IL-8, MMP-2, heparanase, TGF-β, and bFGF
also play an essential part in the process. Because so many
factors are involved with tumor angiogeneses, it is likely that
several of these factors must be inhibited simultaneously in
order to signiﬁcantly reduce the unwanted angiogeneses and
eventual tumor metastasis.
3. FutureDirections
Currently, investigation into mechanisms of angiogeneses
inhibition in cancer is an important and promising area of
research. Prohibiting angiogeneses is an important thera-
peutic approach forﬁghting cancer,reducing atherosclerosis,
and preventing blindness due to retinal neovasculariza-
tion in diabetic patients. In recent years, several new
angiostatic therapies have been tested and approved by
the FDA; examples include Avastin, Tarceva, and Lucentis
[242]; several others are currently being tested in phase III
trials throughout the country. Among them are possible
angiostatic treatments for many diﬀerent types of cancer
including esophageal cancer, pancreatic cancer, lymphoma,
renal cell cancer, gastric cancer, and many others [82].
Important advances have also taken place in deﬁning the
molecular understanding of angiogeneses. This includes a
greater understanding of both angiogeneses as a whole as
well as the mechanism of antiangiogenic drugs currently
being used. However, the many studies using anti-VEGF
treatments illustrate that our knowledge of the angiogenic
pathway remains incomplete. In the past, it was thought that
angiostatic treatment would create a form of cancer treat-
ment that would evade the problem of resistance [243, 244].
As clinical trials continue, it now appears that many tumors
can overcome the use of angiogenic inhibitors, thereby
acquiring a way to bypass the therapeutic angiogeneses
blockade [9, 82, 90]. Although there are several diﬀerent
adaptive mechanisms that tumors may employ to overcome
antiangiogenic therapy, two concepts have emerged as the
most likely candidates [82] .T h eﬁ r s ti st h a tt u m o r sa r ea b l e
to activate or upregulate alternative proangiogenic pathways
after the ﬁrst pathway is inhibited. An example was observed
in animal models when a monoclonal Ab that speciﬁcally
blocked VEGFR signaling was used in mice with tumors.
The mice saw an initial response to the treatment, and the
tumors possessed reduced vascularity [245]. After a short
period of time, however, the tumors saw a reinitiation of
tumor angiogeneses. When the tumors were resected and
studied, they were found to express greater levels of mRNA
for the proangiogenic factors FGF and Ang-1. This change
in expression helps explain one possible method the tumors
are employing to overcome VEGF inhibition. To further
test the eﬀect of upregulation of alternative proangiogenic
factors, a similar study was conducted in which some mice
were treated with VEGF inhibitor alone while others were
treated with a VEGF inhibitor as well as an FGF trap. Mice
treated with combinational therapy saw a great reduction
in vascularization and slowed tumor growth [245]. Yet
another study in mice showed that the induction of IL-8 was
able to maintain angiogenic capability in tumors that did
not express HIF-1α, an inducer of VEGF expression [246].
This alternative pathway illustrates another proangiogenic
pathway that tumors may use to increase vascularization.
Together, these studies have begun to shed light on why
anti-VEGF treatments alone may have seen limited results in
clinical trials.
The other theory to why tumors have been able to
withstand the anti-VEGF treatment is that resistant tumors
have increased pericyte support on their tumor vasculature.
The pericytes are believed to protect the remaining vessels
and defend against the anti-VEGF treatment [219, 247].
The hypothesis states that tumor pericytes are most likely
expressing appreciable levels of VEGF and possibly other
proangiogenic factors [247]. In addition, pericytes are capa-
ble of reducing the rate of EC proliferation which allows
EC maturation and stabilization in newly formed blood
vessels [248]. Currently, several ongoing clinical trials are
attempting to prevent tumor angiogeneses by inhibiting
pericyte association with tumor vasculature along with
angiogenic factors [82, 219].
These two ongoing theories showcase the current prob-
lems in the ﬁeld of antiangiogenic research in cancer. After
several years of clinical trials, it appears that targeting one
angiogenic factor is not enough to permanently halt neo-
vascularization in most tumors. Although these results were
initially disheartening, they also opened up the possibility
of other angiostatic therapies. Many clinical trials now use
existing chemotherapeutic drugs or radiation along with
antiangiogenic drugs. This two-front attack has had more
success than antiangiogenic drugs or chemotherapy alone in
a majority of patients [5, 118, 249].
As research continues, more information is also being
uncovered about the angiogenic pathway. Increased under-
standing of the angiogenic pathway will allow for develop-
ment and use of drugs that can target several angiogenic
factors concurrently, allowing greater inhibition of angio-
geneses, and increasing the likelihood of therapeutic success.
Although the beneﬁt of antiangiogenic treatments has not
been as great as initially anticipated, many advances have
come from their development and clinical use. However,
with time, it is likely that the success of angiogenic treatment
in cancer will continue to improve and we will come ever
closer to the original goal of curing cancer and other
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